Lifeway Foods, Inc. — 2019 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019, compared with fiscal 2018. This is an annual filing, not a standalone fourth-quarter report. Amounts below are in U.S. dollars; financial statement figures are shown in millions unless stated otherwise.
Business context
Lifeway produces and markets kefir and other cultured dairy and probiotic products, primarily in the United States. Drinkable kefir accounted for 77% of 2019 net sales. The company operates one reportable segment and manufactured approximately 99% of 2019 revenue at its own facilities.
Financial performance and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Net sales | $93.662 million | $103.350 million |
| Gross profit / margin | $22.149 million / 23.6% | $25.858 million / 25.0% |
| Operating loss | $(1.933) million | $(3.110) million |
| Net income (loss) | $0.453 million | $(3.086) million |
| Operating cash flow | $3.811 million | $2.417 million |
- Sales fell 9.4%, principally from lower volumes of branded drinkable kefir, cupped kefir and Skyr. New product introductions partly offset the declines.
- Gross margin declined 1.4 percentage points. Management cited sales softness and lower operating leverage, higher freight and depreciation, partly offset by lower variable costs.
- Net income included $3.144 million in investment gains: a $1.731 million fair-value gain and a $1.413 million realized gain. The company remained loss-making at the operating level.
- Cash and cash equivalents were $3.836 million at year-end, up $0.838 million. Investing activities provided net cash of $0.838 million, including $1.509 million from a partial investment sale; financing activities used $3.811 million, primarily for debt repayment and share repurchases.
- Year-end current assets were $19.199 million and current liabilities $9.523 million. Revolver borrowings were $2.745 million, with approximately $5.412 million available under the borrowing base. The company reported compliance with its debt covenants.
- Capital spending was $1.178 million, down from $2.824 million in 2018. No dividends were paid; Lifeway repurchased approximately 211,000 shares for $0.538 million.
Changes, outlook and notable items
- Operating loss narrowed year over year as operating expenses decreased, including lower selling costs and the absence of the $1.244 million goodwill impairment recorded in 2018. However, sales and gross profit declined.
- The 2019 tax provision was $0.782 million, versus a $0.225 million tax benefit in 2018; the reported effective tax rate was 63.3%. Management attributed the high rate to state taxes, nondeductible compensation and uncertain tax positions, among other items.
- Management did not provide quantified financial guidance. It said 2020 product-development efforts were not expected to be a focus, given COVID-19 and an emphasis on expanding sales of existing products.
- COVID-19 was identified as a material uncertainty after year-end. Lifeway reported increased retail orders in March 2020 and no significant disruption to production at that time, but said demand, staffing, supply and distribution effects could not be reliably estimated.
- Goodwill was $9.124 million; the 2019 impairment test found fair value exceeded carrying value by only 2.4%, leaving limited headroom if assumptions weaken. The 2018 material weakness involving review of the goodwill valuation was reported as remediated; management and the auditor found internal control effective at year-end 2019.
- Two customers together represented approximately 22% of 2019 sales. Other risks include dairy-input costs, competition and retailer pricing pressure, supply-chain and food-safety disruptions, and customer or distributor concentration. The company reported ordinary-course legal matters but no material accruals.
- The Smolyansky family controlled approximately 50.5% of common stock. Related-party payments included $1.000 million in consulting fees and $0.588 million in royalties to the board chairperson.
Most important facts for investors to verify
- Whether core kefir volume and total sales stabilize, and whether newer products can offset declines.
- How much of 2019 net income depended on investment gains and whether those gains recur.
- Whether the narrow goodwill valuation cushion remains supportable under updated forecasts and market conditions.
- COVID-19 effects on orders, production, suppliers, transportation and customer demand, including any subsequent-period updates.
- Revolver availability, covenant compliance, customer concentration and the terms and governance implications of related-party arrangements.